Posted by Michael Wonder on 08 Jul 2026
Merck announces FDA breakthrough therapy designation for enpatoran in lupus patients with active skin manifestations
8 July 2026 - Merck today announced that the US FDA has granted breakthrough therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations.
Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation.
